DETROIT, MICHIGAN - August 19, 2025 ( NEWMEDIAWIRE ) - Jupiter Neurosciences Inc . (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™ – an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects – is solidifying its two-pronged business approach with the launch of Nugevia™, its direct-to-consumer longevity product line.
DETROIT, MICHIGAN - July 10, 2025 ( NEWMEDIAWIRE ) - Christer Rosen, chairman & CEO of Jupiter Neurosciences Inc. (NASDAQ: JUNS), was recently a guest on Benzinga’s All-Access.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
DETROIT, MICHIGAN - June 16, 2025 ( NEWMEDIAWIRE ) - While being a biotech company can be difficult, it is not impossible. Just look at Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company, for evidence. The company, which is developing drugs to treat neuroinflammation, with a current focus on central nervous system or CNS disorders such as Alzheimer's and Parkinson's and rare diseases, is taking a two-prong approach. That enables it to help people long-term and generate recurring revenue in the short-term.
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
